On March 5, 2024 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported two upcoming poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting 2024 (April 5-10) in San Diego, California (Press release, Hummingbird Bioscience, MAR 5, 2024, View Source [SID1234640818]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will present pre-clinical data describing the activity of HMBD-001, a clinical-stage anti-HER3 monoclonal antibody (mAb) currently in Phase I trials (NCT05057013, NCT05910827 and NCT05919537), in tumors with oncogenic HER3 mutations, and pre-clinical data investigating the mechanism of action and anti-tumor response of HMBD-002, a clinical-stage anti-VISTA mAb currently in Phase I trials (NCT05082610).
HMBD-001 is shown to potently block oncogenic signaling driven by HER3 mutations and could offer significant clinical benefit for patients with HER3 mutations across cancer types. The poster will highlight that more than 80% tumor growth inhibition is seen across multiple preclinical models with common HER3 mutations. The data also confirms that HMBD-001’s binding epitope does not overlap with these mutations in HER3.
HMBD-002 selectively blocks VISTA while avoiding depletion of important immune cell populations, holding significant promise for patients with aggressive cancers, including triple-negative breast cancer and non-small cell lung cancer. The HMBD-002 poster will highlight the molecular and cellular mechanisms driving HMBD-002’s specific and potent anti-tumor response via VISTA blockade. These insights will help to identify and target patients that are most likely to benefit from HMBD-002.
"These translational studies exemplify Hummingbird Bio’s commitment to precision oncology. Through better understanding of disease biology and the mechanisms underlying the efficacy of our therapies, we can more precisely define the patient populations that will benefit from those therapies. We look forward to discussing our recent advancements with the oncology research community at AACR (Free AACR Whitepaper)," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience.
Hummingbird Bioscience is recruiting patients with aberrant HER3 signaling, which includes selected HER3 mutations, in the company’s ongoing Phase Ib trial (NCT05919537).
HMBD-001
Presentation
Title: A HER3 antibody that uniquely
blocks the HER3 heterodimerization
interface effectively inhibits tumor
growth in pre-clinical models with
potentially oncogenic HER3
mutations
Session Category: Experimental and
Molecular Therapeutics
Session Title: Cancer Treatment: New
Technologies
Session Date and Time: Tuesday Apr 9,
2024, 1:30 PM – 5:00 PM
Location: Poster Section 22
Poster Board Number: 5
Published Abstract Number: 5796
HMBD-002
Presentation
Title: The VISTA blocking antibody
HMBD-002 promotes type-I
interferon signaling and drives anti-
tumor responses through
macrophage reprograming and
cytotoxic CD8+ T cell activation
Session Category: Immunology
Session Title: Immune Checkpoints and
Inhibitory Molecules 1
Session Date and Time: Monday Apr 8,
2024, 9:00 AM – 12:30 PM
Location: Poster Section 3
Poster Board Number: 7
Published Abstract Number: 1356